Patents by Inventor Jeff A. Zablocki

Jeff A. Zablocki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
    Publication number: 20080255161
    Abstract: The present invention discloses 3-hydroquinazolin-4-one derivatives for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cancer, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.
    Type: Application
    Filed: April 9, 2008
    Publication date: October 16, 2008
    Inventors: Dmitry Koltun, Eric Parkhill, Melanie Boze, Jeff Zablocki, Natalya Vasilevich, Elena Mayboroda, Andrei Glushkov, Andrew Cole, Jeffrey Chisholm
  • PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
    Publication number: 20080249100
    Abstract: The present invention discloses pteridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.
    Type: Application
    Filed: October 5, 2007
    Publication date: October 9, 2008
    Inventors: Jeffrey Chisholm, Dmitry Koltun, Jeff Zablocki, Eric Parkhill, Andrey Glushkov, Natalya Vasilevich, Timur Zilbershtein, Andrew Cole, Tsung Lin, Ian Henderson
  • QUINAZOLINONE DERIVATIVES AS ALDH-2 INHIBITORS
    Publication number: 20080249116
    Abstract: Disclosed are novel quinazolinone derivatives, useful as ALDH-2 inhibitors for treating mammals for various disease states, such as treatment for cocaine dependency or alcohol dependency.
    Type: Application
    Filed: April 3, 2008
    Publication date: October 9, 2008
    Inventors: Jeff Zablocki, Matthew Abelman, Michael Organ
  • ABCA1 elevating compounds
    Patent number: 7432276
    Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: October 7, 2008
    Assignee: CV Therapeutics, Inc.
    Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun, Melanie Boze
  • ABCA1 elevating compounds
    Patent number: 7423045
    Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: September 9, 2008
    Assignee: CV Therapeutics, Inc.
    Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun
  • ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION
    Publication number: 20080207610
    Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.
    Type: Application
    Filed: January 24, 2008
    Publication date: August 28, 2008
    Inventors: Jeff Zablocki, Matthew Abelman, Michael Organ, Yaroslav Bilokin, Robert Jiang, Elfatih Elzein, Tetsuya Kobayashi, Rao Kalla, Thao Perry, Xiaofen Li, Ivan Diamond, Lina Yao, Peidong Fan, Maria Pia Arolfo, Zhan Jiang
  • A2B ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20080194593
    Abstract: Disclosed are methods for treating asthma, inflammatory gastrointestinal tract disorders, cancer, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis using A2B adenosine receptor antagonists having the structure of Formula I or Formula II:
    Type: Application
    Filed: January 11, 2008
    Publication date: August 14, 2008
    Inventors: Rao Kalla, Thao Perry, Elfatih Elzein, Xiaofen Li, Jeff Zablocki, Dewan Zeng, Dengming Xiao, Vaibhav Varkhedkar, Prabha Ibrahim, Venkata Palle, Hongyan Zhong
  • A2A ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20080188495
    Abstract: The present invention relates to novel compounds that are A2A adenosine receptor antagonists, and to their use in treating mammals for various disease states, such as CNS disorders, including the “movement disorders” (Parkinson's disease, Huntington's Chorea, and catalepsy), and cerebral ischemia, excitotoxicity, cognitive and physiological disorders, depression, ADHD, hepatic fibrosis, cirrhosis of the liver, and drug addiction (alcohol, amphetamine, cannabinoids, cocaine, nicotine, and opioids) and to their use in the enhancement of immune response. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    Type: Application
    Filed: November 29, 2007
    Publication date: August 7, 2008
    Inventors: Tetsuya Kobayashi, Rao Kalla, Elfatih Elzein, Jeff Zablocki, Brent Blackburn
  • Substituted heterocyclic compounds
    Patent number: 7407960
    Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: August 5, 2008
    Assignee: CV Therapeutics, Inc.
    Inventors: Elfatih Elzein, Dmitry Koltun, Jeff Zablocki
  • A2B ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20080153856
    Abstract: Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.
    Type: Application
    Filed: December 3, 2007
    Publication date: June 26, 2008
    Inventors: Rao Kalla, Thao Perry, Elfatih Elzein, Vaibhav Varkhedkar, Xiaofen Li, Prabha Ibrahim, Venkata Palle, Dengming Xiao, Jeff Zablocki
  • BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
    Publication number: 20080139570
    Abstract: The present invention discloses bicyclic nitrogen-containing heterocyclic compounds for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, oily skin conditions, metabolic syndrome, and the like.
    Type: Application
    Filed: October 5, 2007
    Publication date: June 12, 2008
    Inventors: Jeffrey Chisholm, Dmitry Koltun, Jeff Zablocki, Eric Parkhill, Andrey Glushkov, Natalya Vasilevich, Timur Zilbershtein, Alexey Ivanov
  • A1 adenosine receptor agonists
    Patent number: 7381714
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: June 3, 2008
    Assignee: CV Therapeutics, Inc.
    Inventors: Elfatih Elzein, Rao Kalla, Thao Perry, Jeff Zablocki, Xiaofen Li
  • A2B ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20080085908
    Abstract: Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.
    Type: Application
    Filed: December 5, 2007
    Publication date: April 10, 2008
    Inventors: Rao Kalla, Thao Perry, Elfatih Elzein, Vaibhav Varkhedkar, Xiaofen Li, Prabha Ibrahim, Venkata Palle, Dengming Xiao, Jeff Zablocki
  • Substituted Heterocyclic Compounds
    Publication number: 20080070927
    Abstract: Disclosed are novel piperazine and piperazine derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, diabetes, intermitten claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Application
    Filed: September 17, 2007
    Publication date: March 20, 2008
    Inventors: Jeff Zablocki, Dmitry Koltun
  • ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION
    Publication number: 20080032995
    Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.
    Type: Application
    Filed: July 27, 2007
    Publication date: February 7, 2008
    Inventors: Jeff Zablocki, Matthew Abelman, Michael Organ, Yaroslav Bilokin, Ivan Diamond, Maria Arolfo, Lina Yao, Peidong Fan, Elfatih Elzein, Rao Kalla, Thao Perry, Tetsuya Kobayshi, Xiaofen Lee, Robert Jiang
  • Aadenosine receptor antagonists
    Patent number: 7317017
    Abstract: Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: January 8, 2008
    Assignee: CV Therapeutics, Inc.
    Inventors: Rao Kalla, Thao Perry, Elfatih Elzein, Vaibhav Varkhedkar, Xiaofen Li, Prabha Ibrahim, Venkata Palle, Dengming Xiao, Jeff Zablocki
  • Aadenosine receptor antagonists
    Patent number: 7304070
    Abstract: Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: December 4, 2007
    Assignee: CV Therapeutics, Inc.
    Inventors: Rao Kalla, Thao Perry, Elfatih Elzein, Vaibhav Varkhedkar, Xiaofen Li, Prabha Ibrahim, Venkata Palle, Dengming Xiao, Jeff Zablocki
  • Partial and full agonists of A1 adenosine receptors
    Patent number: 7300923
    Abstract: Disclosed are syntheses suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
    Type: Grant
    Filed: August 29, 2005
    Date of Patent: November 27, 2007
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff Zablocki, Elfatih Elzein, Michael Organ, Yaroslav Bilokin, Stanislas Mayer, Anthony Disanti, Scott Miller, Peter Kernast
  • Process for preparing an A2A-adenosine receptor agonist and its polymorphs
    Publication number: 20070265445
    Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
    Type: Application
    Filed: February 2, 2007
    Publication date: November 15, 2007
    Inventors: Jeff Zablocki, Elfatih Elzein
  • PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS
    Publication number: 20070225247
    Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
    Type: Application
    Filed: May 17, 2007
    Publication date: September 27, 2007
    Inventors: Jeff Zablocki, Elfatih Elzein